This bill aims to enhance prescription drug coverage for the treatment of obesity in Washington State by adding new provisions to the state's Medicaid and public employee health benefit plans. The legislation recognizes obesity as a serious health condition linked to major health risks and acknowledges the recent approval of new medications by the U.S. Food and Drug Administration (FDA) for chronic weight management. The bill intends to include these FDA-approved drugs, specifically glucagon-like peptide 1 agonists and similar medications, in the state's Medicaid preferred drug list and mandates that public employee health benefit plans provide coverage for these treatments starting January 1, 2025.

To implement this, the bill introduces new sections to chapters 41.05 and 74.09 of the Revised Code of Washington (RCW). It stipulates that health benefit plans for public employees must cover the specified medications when prescribed for patients classified as obese, defined as having a body mass index (BMI) of 30 or more, or those with a BMI of at least 27 who also have a weight-related medical condition. Additionally, Medicaid managed care organizations are required to provide similar coverage under the new provisions.